Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2022-12-07 Regulatory Filings
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated December 7, 2022, announcing that the company's product, BIOCERA-VET®, was nominated for a Veterinary Innovation Award at the AFVAC 2022 conference. It also mentions participation in other veterinary congresses. This type of announcement, detailing company news, product recognition, and participation in industry events, is characteristic of a general corporate announcement or press release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of material, non-financial news.
2022-12-07 French
PR - TheraVet - USA distribution agreement_final.pdf
M&A Activity Classification · 99% confidence The document is a press release announcing an exclusive distribution agreement for BIOCERA-VET® products in the USA between TheraVet and Invictos Orthopedics. This type of announcement, detailing a significant business development, partnership, or commercial agreement, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or shareholder event categories (like AGM-R, DEF 14A). It is a general corporate announcement regarding business operations and expansion. Since it is not a formal regulatory filing like a 10-K or a specific financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS), which often serves as a catch-all for material press releases that aren't explicitly covered elsewhere, especially those related to commercial strategy and market expansion.
2022-09-26 English
CP - TheraVet - USA Accord de distribution_final.pdf
Regulatory Filings Classification · 100% confidence The document is a press release from TheraVet announcing the signing of an exclusive distribution agreement for its BIOCERA-VET® product line in the United States with Invictos Orthopedics. This type of announcement, detailing a significant business development, partnership, or commercial agreement, does not fit the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate announcement regarding business operations and strategy. Since it is not a standard regulatory filing like a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ), and it is not a formal report publication announcement (RPA) but the content itself, the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS, as it is a formal communication to the market about a material event.
2022-09-26 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing TheraVet's participation in the 2022 ESVOT Congress, detailing the scientific communications (posters and oral presentations) that will be presented. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about company activities and scientific updates intended for investors and the public. Since it doesn't fit the specific categories like AGM-R, ER, IR, or CT, and it is a general corporate announcement, the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous corporate news releases that don't fit other specific types, although 'Investor Presentation' (IP) is related to congress participation, this document is the *announcement* of participation, not the presentation itself. Given the nature of the announcement (scientific participation and commercial presence), RNS is the best fit as a general corporate news item.
2022-09-19 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from TheraVet announcing its participation in the ESVOT 2022 congress, detailing the scientific presentations and commercial presence. This type of announcement, which communicates company activities, scientific updates, or participation in industry events, does not fit the specific definitions for mandatory financial filings (10-K, IR, ER, etc.) or specific corporate actions (DIV, CAP, DIRS). It is a general corporate update. Since it is not a standard regulatory filing like an 8-K or a specific report, and it is not a transcript, presentation, or factsheet, the most appropriate general category for non-standard corporate news announcements is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous regulatory or significant corporate news releases that don't fit elsewhere, although 'Investor Presentation' (IP) or 'Report Publication Announcement' (RPA) are sometimes used for event-related news. Given the content is an announcement about participation and presentations, and not the presentation itself, RNS is the best fit among the available options for a general corporate news release.
2022-09-19 French
Rapport Financier semestriel 2022_signé.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2022' (Semi-Annual Financial Report 2022) for TheraVet SA. It contains comprehensive financial statements, including the balance sheet, income statement, cash flow analysis, and management's discussion and analysis for the six-month period ending June 30, 2022. It is not a mere announcement or certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-09 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.